ADC Therapeutics SA financials

ADCT CIK 0001771910

Source: EDGAR filings · Built 2026-06-02T02:14:30Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2023FY 2021
Free Cash Flow -141.44M -124.70M -121.90M -139.00M
EBITDA -120.79M -129.32M -164.80M -122.28M
Working Capital 236.17M 210.78M 268.62M 353.04M
Net Debt -144.26M -127.90M -266.95M -318.78M
Gross Margin 92.87% 91.60% 96.34% 95.59%
Operating Margin -149.34% -184.44% -240.35% -164.66%
Net Margin -175.31% -222.83% -347.60% -209.76%
Return on Equity (ROE) 76.75% 77.89% 161.93% -197.77%
Return on Assets (ROA) -44.14% -49.02% -67.66% -32.01%
Current Ratio 4.37× 3.62× 4.97× 5.31×
Debt-to-Equity -0.63× -0.61× -0.08× 0.10×
Effective Tax Rate -0.72% -0.11% -20.01% -0.15%
Cash Conversion Ratio 0.99× 0.78× 0.49× 0.88×
Accruals Ratio -0.00× -0.11× -0.34× -0.04×
SBC % of Revenue 8.49% 9.27% 19.54% 65.84%
CapEx Coverage -534.75× -142.83× -36.90× -201.33×
Free Cash Flow Per Share $-1.11 $-1.28 $-1.49 $-1.78

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2023FY 2021
P/S 5.46× 2.78× 1.98× 4.13×
P/B 3.90× 10.07×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2023FY 2021
Revenue from Contract with Customer, Excluding Assessed Tax 69.06M 74.91M
Revenues 81.36M 70.84M 69.56M 209.91M
Cost of Revenue 5.80M 5.95M 2.53M 3.30M
Research and Development Expense 104.00M 109.63M 127.13M 186.46M
Operating Income (Loss) -121.50M -130.65M -165.99M -123.34M
Income Tax Expense (Benefit) 1.01M 166.00K 39.11M 227.00K
Net Income (Loss) Attributable to Parent -142.62M -157.85M -240.05M -157.13M
Earnings Per Share, Basic $-1.12 $-1.62 $-2.94 $-2.01
Weighted Average Number of Shares Outstanding, Basic 127.07M 97.16M 81.71M 78.15M
Earnings Per Share, Diluted $-1.12 $-1.62 $-2.94 $-2.01
Weighted Average Number of Shares Outstanding, Diluted 127.07M 97.16M 81.71M 78.15M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2023FY 2021
Cash and Cash Equivalents, at Carrying Value 261.34M 250.87M 278.60M 326.44M
Assets, Current 306.33M 291.25M 336.29M 434.98M
Assets 323.15M 321.98M 354.78M 490.86M
Liabilities, Current 70.16M 80.47M 67.67M 81.94M
Liabilities 508.98M 524.62M 503.03M 411.41M
Stockholders' Equity Attributable to Parent -185.83M -202.64M -148.25M 79.45M 154.03M
Common Stock, Shares, Outstanding 125.75M 98.86M 82.29M 80.64M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2023FY 2021
Net Cash Provided by (Used in) Operating Activities -141.17M -123.83M -118.69M -138.31M
Payments to Acquire Property, Plant, and Equipment 264.00K 867.00K 3.22M 687.00K
Net Cash Provided by (Used in) Investing Activities 395.00K -867.00K -3.22M -687.00K
Net Cash Provided by (Used in) Financing Activities 150.94M 97.05M 73.88M -897.00K

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ADCT CIK 0001771910), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

NG

NOVAGOLD RESOURCES INC.

VSEC

VSE CORPORATION

DUOT

Duos Technologies Group, Inc.